L3VLUP
ProSign in

INSM · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INSMJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INSM
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterINSMJNJ
Q3 20209 holders, $1.2bn30 holders, $26.2bn
Q4 20208 holders, $1.0bn32 holders, $26.6bn
Q1 20216 holders, $816m31 holders, $25.3bn
Q2 20216 holders, $800m37 holders, $25.6bn
Q3 20217 holders, $803m40 holders, $24.1bn
Q4 20217 holders, $760m33 holders, $25.2bn
Q1 20228 holders, $680m35 holders, $28.2bn
Q2 20227 holders, $566m33 holders, $26.9bn
Q3 202210 holders, $379m36 holders, $25.4bn
Q4 20228 holders, $360m35 holders, $27.6bn
Q1 20236 holders, $282m42 holders, $24.5bn
Q2 20236 holders, $353m38 holders, $25.0bn
Q3 20237 holders, $415m37 holders, $18.9bn
Q4 20238 holders, $539m31 holders, $19.0bn
Q1 20248 holders, $437m32 holders, $19.7bn
Q2 202416 holders, $2.2bn35 holders, $20.4bn
Q3 202418 holders, $2.3bn28 holders, $22.3bn
Q4 202414 holders, $1.6bn37 holders, $20.4bn
Q1 202514 holders, $1.9bn32 holders, $20.5bn
Q2 202523 holders, $3.7bn31 holders, $18.4bn
Q3 202520 holders, $5.8bn32 holders, $23.7bn
Q4 202519 holders, $6.6bn29 holders, $27.8bn
Q1 202619 holders, $7.0bn34 holders, $35.6bn
Q2 202621 holders, $5.0bn33 holders, $39.1bn
INSM

Insmed Inc

Holders
8
Reported value
$437m
Buyers
7
Sellers
3

Breadth +4 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$19.7bn
Buyers
16
Sellers
13

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INSM (1)

Schonfeld Strategic Advisors LLC

Only JNJ (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →